Skip to main content
Equibles
IMVT logo

IMVT · Immunovant, Inc. · Metrics

Track IMVT — free

Use IMVT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IMVT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$28.41 -0.69 (-2.37%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$5.87B
Shares
206.55M
Volume · Oct 23 641.46K Avg daily vol (3M) 1.33M

IMVT metrics

59 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$28.41
Market cap
$5.87B

Price action

20 metrics
Price change (1W)
+6.3%
Price change (30D)
-14.7%
Price change (3M)
-27.9%
Price change (6M)
-0.6%
Price change (YTD)
+11.8%
Price change (1Y)
+51.6%
Trailing year
Price change (5Y)
+242.3%
52-week high
$44.96
52-week low
$18.74
Change from 52-week high
-36.8%
Change from 52-week low
+51.6%
Annualized volatility
59.0%
Annualized volatility (3M)
36.2%
Beta
1.4
RSI (14D)
31.9
Price vs SMA 50
-21.2%
Price vs SMA 200
-11.1%
Avg volume (3M)
1.33M
Relative volume
0.5
Average dollar volume
$48.27M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
206.55M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
8.0
reciprocal yield 12.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-09
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
−$538.22M
Trailing 12 months
Diluted EPS (TTM)
$-2.81
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.18

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+20.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-73.2%
Return on assets
-63.1%
Debt / equity
—
Current ratio
7.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$797.80M
Latest balance sheet
Cash & equivalents
$797.80M
Total assets
$852.49M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$414.30M
Capital expenditures (TTM)
$8,000
R&D (TTM)
$498.09M
SG&A (TTM)
—
Stock compensation (TTM)
$50.99M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
229
13F filer change QoQ
+11
Institutional ownership
54.4%
Conviction holders (share of 13F filers)
3.1%
Crowding (high-turnover and private-fund holders)
19.2%
Private-fund adviser ownership
17.3%
Active holders' share change QoQ
-2.2%
Holder tenure
13.3
Price vs estimated holder cost
+59.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.4%

Short interest

3 metrics
Short interest
8.4%
Latest settlement · 9.6 days to cover
Days to cover
9.6d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$659,435
Insider-sentiment score
30 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1764013 CUSIP 45258J102 13F (30d) 23 filings 23 filers Visit website Investor relations